Aditya Hadi Pratama · · 1 min readASTAR healthtech startup spin-off bags $3.4m seed funding
Respiree, a Singapore-based healthtech startup, has raised S$4.7 million (around US$3.4 million) in a seed round led by Oriza Greenwillow Technology Fund, Seeds Capital, and She1k.
Image source: Respiree
Founded by Gurpreet Singh in 2019, Respiree developed cardiopulmonary sensors that are integrated into its virtual care platform. The devices can track clinical deterioration more efficiently.
Singapore’s Health Sciences Authority, the European Commission, and Australia’s Therapeutics Good Administration have already medically approved the product. The firm is also currently securing approval for its sensor from the US Food and Drug Administration.
Respiree is a spin-off from the Agency for Science, Technology, and Research (ASTAR), a Singapore research and development agency.
Amid the pandemic, local hospitals in Singapore have used the company’s solution to check on Covid-19 patients. Respiree has also partnered with prominent health companies such as AstraZeneca, the Singapore National University Hospital, and Changi General Hospital.
See also: Series SEA: Who’s investing in the region’s health startups?
The company plans to use the fresh funds to scale the use of its cardiopulmonary sensors in the US, Australia, and Singapore.
Editing by Miguel Cordon and Jaclyn Tiu
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
